BioMarin Pharma (BMRN) Posts Q4 Loss of $0.53
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $59.59 -0.68%
Revenue Growth %: +13.9%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
UBAB, LOAN, FITB, More
Revenue Growth %: +13.9%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
UBAB, LOAN, FITB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.53), which may not compare to the analyst estimate of ($0.38). Revenue for the quarter came in at $300 million versus the consensus estimate of $295.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
- Autoliv (ALV) Reports In-Line Q2 EPS
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $76 at Citi
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
